Bavarian Nordic A/S Stock

Bavarian Nordic A/S Liabilities 2024

Bavarian Nordic A/S Liabilities

4.01 B DKK

Ticker

BAVA.CO

ISIN

DK0015998017

WKN

917165

In 2024, Bavarian Nordic A/S's total liabilities amounted to 4.01 B DKK, a -23.43% difference from the 5.24 B DKK total liabilities in the previous year.

Bavarian Nordic A/S Aktienanalyse

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S is a biopharmaceutical company based in Denmark, specializing in the development and production of vaccines. The company was established in 1994 as a spin-off from the University of Copenhagen and has been listed on the Copenhagen stock exchange since 1998. The company's history began with an innovation developed by Professor Peter Andersen at the University of Copenhagen - the Viruslike Particles (VLP) technology. This technology serves as the basis for the production of vaccines against severe infectious diseases such as influenza, RSV, or HPV. Bavarian Nordic utilizes this technology to generate effective immune responses without using live pathogens. The company's business model is focused on two areas: the commercial vaccine sector and the biodefense products sector. The commercial sector includes the development and production of vaccines for cancer (such as prostate cancer or breast cancer) as well as infectious diseases like RSV. The biodefense products sector concentrates on protection against biological attacks, with the company manufacturing vaccines against bioweapons such as anthrax or smallpox for governmental institutions. Bavarian Nordic is divided into various business divisions. One of these is the commercial vaccines department, which develops and produces vaccines for the commercial market, particularly for cancer indications. The company also has a biodefense products department, which safeguards governmental institutions and organizations against bioterrorist attacks and other threats posed by biological weapons. This department focuses on the development and production of vaccines against smallpox, anthrax, and Ebola virus. Bavarian Nordic offers a wide range of products. The commercial vaccine Prostvac against prostate cancer is the company's flagship product. Other vaccines that have been developed or are still in development include vaccines against breast cancer, influenza, RSV, and lung cancer. The biodefense products encompass vaccines against smallpox, anthrax, and Ebola virus, as well as preclinical development programs for additional biological attacks. The company has also signed cooperation agreements with other companies to accelerate the research and development of new products. These include collaborations with Bristol Myers Squibb and Janssen Pharmaceutica for the development of cancer vaccines, as well as with the British Ministry of Defence for the development of vaccines against anthrax. Overall, Bavarian Nordic A/S caters to a broad range of interests and business sectors. The company focuses on the development and production of vaccines for both commercial and governmental institutions, aiming to enhance protection against biological threats and infectious diseases. Thanks to its innovative VLP technology, the company is a key player in the field of vaccine development and offers a wide range of products. Bavarian Nordic A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Bavarian Nordic A/S's Liabilities

Bavarian Nordic A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bavarian Nordic A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Bavarian Nordic A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Bavarian Nordic A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Bavarian Nordic A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Bavarian Nordic A/S stock

What is the level of liabilities of Bavarian Nordic A/S this year?

Bavarian Nordic A/S has a debt balance of 4.01 B DKK this year.

What were the liabilities of Bavarian Nordic A/S compared to the previous year?

The liabilities of Bavarian Nordic A/S have increased by -23.43% dropped compared to the previous year.

What are the consequences of high debt for investors of Bavarian Nordic A/S?

High liabilities can pose a risk for investors of Bavarian Nordic A/S, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Bavarian Nordic A/S?

Low liabilities mean that Bavarian Nordic A/S has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Bavarian Nordic A/S affect the company?

An increase in liabilities of Bavarian Nordic A/S can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Bavarian Nordic A/S affect the company?

A decrease in the liabilities of Bavarian Nordic A/S can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Bavarian Nordic A/S?

Some factors that can influence the liabilities of Bavarian Nordic A/S include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Bavarian Nordic A/S so important for investors?

The liabilities of Bavarian Nordic A/S are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Bavarian Nordic A/S take to modify the liabilities?

To change its liabilities, Bavarian Nordic A/S can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Bavarian Nordic A/S pay?

Over the past 12 months, Bavarian Nordic A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bavarian Nordic A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Bavarian Nordic A/S?

The current dividend yield of Bavarian Nordic A/S is .

When does Bavarian Nordic A/S pay dividends?

Bavarian Nordic A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bavarian Nordic A/S?

Bavarian Nordic A/S paid dividends every year for the past 0 years.

What is the dividend of Bavarian Nordic A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bavarian Nordic A/S located?

Bavarian Nordic A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bavarian Nordic A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bavarian Nordic A/S from 7/29/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 7/29/2024.

When did Bavarian Nordic A/S pay the last dividend?

The last dividend was paid out on 7/29/2024.

What was the dividend of Bavarian Nordic A/S in the year 2023?

In the year 2023, Bavarian Nordic A/S distributed 0 DKK as dividends.

In which currency does Bavarian Nordic A/S pay out the dividend?

The dividends of Bavarian Nordic A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Bavarian Nordic A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Bavarian Nordic A/S

Our stock analysis for Bavarian Nordic A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bavarian Nordic A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.